Research on the Optimization of Treatment for Spinal Metastases With Radioactive Particle Implantation Using TPS and Mechanical Dual Simulation

Inclusion Criteria: * Age ≥18 years. Radiologically or histologically confirmed bone metastasis with a lesion suitable for percutaneous radioactive seed implantation (e.g., I-125), per multidisciplinary assessment. Indication for local palliation/control: moderate-to-severe pain at lesion (e.g., BPI/VAS ≥4) and/or imaging evidence of progression or high-risk features warranting local therapy. Measurable/evaluable target lesion on CT/MRI; target location accessible for needle placement per institutional practice. ECOG performance status 0-2. Estimated life expectancy ≥3 months. Adequate hemostasis: platelets ≥80×10\^9/L, INR ≤1.5 (or per protocol), and able to hold/bridge anticoagulation as clinically indicated. Adequate organ function to undergo the procedure and anesthesia/sedation per site standards. Able to undergo required imaging (CT; MRI if applicable). Willing and able to provide written informed consent and comply with follow-up. For women of childbearing potential and men with partners of childbearing potential: agreement to use effective contraception during and for the protocol-defined period after implantation. Exclusion Criteria: * Need for urgent surgical decompression or stabilization (e.g., acute/impending neurologic compromise, unstable pathologic fracture) that precludes percutaneous implantation at this time. Uncorrected coagulopathy or ongoing antithrombotic therapy that cannot be safely managed periprocedurally. Active systemic or local inf…